Ari M. Melnick
Ari M. Melnick
Biology of the immune system; lymphomas and leukemias; epigenetics; cancer experimental therapeutics
Current Research Interest
Mechanisms through which the epigenome programs the normal immune response; how mutations in epigenetic modifier genes causes lymphoma; the molecular epigenetic blueprints that determine the biology of acute leukemias; novel therapeutic agents and regimens for patients with lymphomas and leukemias
Sidney Kimmel Foundation Scholar in Cancer Research
Leukemia and Lymphoma Society Scholar
American Society of Hematology Scholar Award
Burroughs Wellcome Fund Clinical Scientist Award in Translational Research
American Society of Clinical Investigation
Association of American Physicians
Béguelin, Wendy, Marín A. Rivas, María T. Calvo Fernández, Matt Teater, Alberto Purwada, David Redmond, Hao Shen, Matt F. Challman, Olivier Elemento, Ankur Singh, and Ari M. Melnick. “EZH2 Enables Germinal Center Formation Through Epigenetic Silencing of CDKN1A and an Rb-E2F1 Positive Feedback Loop.” Nature Communications 8, no.1 (2017): 877.
Jiang, Yanwen, Ana Ortega-Molina, Hsia-Yuan Ying, Huimin Geng, Dylan McNally, Ling Wang, Ashley S. Doane, Xabier Agirre, Matt Teater, Cem Meydan, Zhuoning Li, David Polaway, Sara Parsa, Shenqiu Wang, Daisuke Ennishi, David W. Scott, Rita Shaknovich, Randy D. Gascoyne, Wayne Tam, Olivier Elemento, Hans-Guido Wendel, and Ari M. Melnick. “CREBBP Inactivation Promotes the Development of HDAC3 Dependent Lymphomas.” Cancer Discovery 7, no.1 (2017): 38-53.